JCEM: Body mass index increase is associated with decreases in antimuller hormones.

For women with and without polycystic ovary syndrome (PCOS), whether and how body mass index (BMI) affects antimuller hormone (AMH) has been debated.
understanding the relationship between BMI-AMH is critical to the clinical interpretation of laboratory test results and may shed light on potential ovarian physiology mechanisms.
Recently, a study published in Journal of Clinical Endocrinology and Metabolism, a leading journal in the field of endocrine and metabolic diseases, examined the hypothesis that (1) BMI was associated with lower AMH in women with PCOS and ovarian control (OVA), and (2) dilution effects did not explain the decrease in AMH levels.
the study was a multi-center cohort study of women aged 25-40 from two clinical groups: 640 PCOS and 921 ovulation control (OVA).
observations in the study were the ovarian reserve index: AMH; sinus follicle count (AFC); and the ratio of AMH to AFC (AMH/AFC).
adjusted for age, race, smoking, and region in the multi-factor regression model, increases in BMI and waist circumference (WC) were associated with decreases in AMH and AMECs in both queues.
increase in BMI is associated with a decrease in AFC in PCOS patients, but not with OVA.
body surface area (BSA), which, unlike BMI, is directly related to plasma volume to explore the potential dilution effect of human size on AMH concentrations.
that after controlling the BSA, the BMI in both queues retains a separate association with the AMH.
no longer has an association between BSA and AMH.
adjusted analysis, BMI (not BSA) was associated with AMC reduction;
AMH produced by follicles may be the cause of lower AMC due to elevated BMI.
.